Cheelcare Announces Fourth Quarter and Fiscal 2026 Financial Results and Provides Curio Update

Cheelcare reports 22% revenue growth but omits key financial details.

What the company is saying

Cheelcare Inc. communicates a positive narrative by highlighting a 22% year-over-year revenue increase for fiscal 2026. The announcement frames this as evidence of continued revenue and Companion sales growth, but does not provide any specific figures for Companion sales or absolute revenue numbers. The language is upbeat but lacks detail, focusing on topline momentum without addressing profitability, margins, or cash flow. The company presents this as a financial results release, yet only discloses a single percentage growth figure. No management commentary or named individuals are cited, and there is no discussion of operational challenges or risks. The emphasis is on topline growth, while the absence of segment breakdowns and profitability metrics is not addressed.

What the data suggests

The only concrete figure disclosed is a 22% increase in fiscal 2026 revenue compared to the prior year. No absolute revenue numbers are provided, so the scale of the business remains unclear. There is no breakdown of revenue by product line, including the referenced Companion sales, nor are any profitability, margin, or cash flow metrics disclosed. The lack of detail prevents assessment of operational efficiency, cost structure, or the sustainability of growth. No information is given about customer concentration, geographic performance, or recurring versus one-time revenue. The data quality is low, with transparency limited to a single topline growth metric. An independent analyst would conclude that while revenue momentum is positive, the absence of supporting detail leaves the overall financial health and trajectory uncertain.

Analysis

The announcement is positive in tone, highlighting a 22% year-over-year revenue increase for fiscal 2026. This is a realised, not forward-looking, claim and is supported by the disclosed numerical data. However, the disclosure is minimal: there are no absolute revenue figures, no profitability metrics (net income, EBITDA, operating profit, or cash flow), and no segment breakdowns (such as for Companion sales). The language is not exaggerated, and there are no aspirational or speculative statements. The gap between narrative and evidence is limited to the lack of detail, not overstatement. The absence of profit or cash flow data means the signal cannot be stronger than weak_positive, but there is no hype or inflation present.

Risk flags

• ●Disclosure risk is high because only a single percentage growth figure is provided, with no absolute revenue, profitability, or cash flow data. This lack of transparency makes it difficult for investors to assess the company's financial health or compare performance across periods.
• ●Operational risk remains unaddressed since there is no discussion of cost structure, margins, or the sustainability of revenue growth. Without these details, investors cannot determine if growth is being achieved efficiently or at the expense of profitability.
• ●Segment risk is present because the announcement references 'Companion sales growth' without providing any figures or segment breakdowns. This omission prevents analysis of which products or business lines are driving performance and whether growth is broad-based or concentrated.

Bottom line

Cheelcare's announcement confirms a 22% year-over-year revenue increase for fiscal 2026 but omits all other financial details, including absolute revenue, profitability, and segment performance. The narrative is positive but lacks the supporting data investors typically expect in a financial results release. Without more granular disclosure, it is impossible to assess whether growth is sustainable, profitable, or concentrated in specific products. The absence of management commentary or operational context further limits insight. For this announcement to be actionable, the company would need to provide a full set of financial statements, including segment breakdowns and profitability metrics. The most important takeaway is that while topline growth is positive, the lack of detail leaves the company's true financial position unclear.

Announcement summary

(TSXV: CHER) Cheelcare Inc. announced its financial results for the fourth quarter and fiscal year ended April 30, 2026. Fiscal 2026 revenue increased 22% year-over-year to $1,908,941, compared to $1,569,887 in fiscal 2025. The Company sold 536 Companion units during the year, up from 453 in fiscal 2025, representing an 18% increase in annual unit sales. Gross profit for fiscal 2026 was $464,525, or approximately 24% of revenue, compared to $663,963, or approximately 42%, in fiscal 2025, with the decrease impacted by a $443,000 inventory write-off and the reclassification of direct assembly labour costs to cost of sales. Net loss for fiscal 2026 was $4,859,475, or $0.27 per share, compared to a net loss of $1,270,041, or $0.12 per share, in fiscal 2025, including a $1,341,974 listing expense, a $494,238 loss on derivative instrument, and a $312,209 loss on debt settlement. In the fourth quarter ended April 30, 2026, revenue was $628,407, compared to $352,194 in Q4 2025, an increase of approximately 78%. The Company reported a gross loss of $185,033 in Q4 2026, compared to gross profit of $79,402 in Q4 2025, primarily due to a $443,000 inventory write-off and reclassification of direct assembly labour costs. Net loss for Q4 2026 was $2,172,093, compared to $750,714 in Q4 2025, with the quarterly loss including the $312,209 loss on debt settlement and continued investment in research and development, staffing, and manufacturing and commercialization infrastructure. The Company surpassed 2,000 cumulative Companion units sold since product launch and distributes its products through more than 500 dealer locations globally, including more than 200 in the United States, 267 in Ontario, and more than 35 U.S. Veterans Affairs Medical Centers. Cheelcare transitioned to a new 16,000 sq. ft. production facility during the year, with operations commencing in October 2025. On January 26, 2026, the Companion power-assist device received PDAC verification, establishing reimbursement eligibility through U.S. Medicare and Medicaid programs. Subsequent to year-end, on July 3, 2026, the Company completed a private placement of 2,015,500 units at a price of $1.50 per unit for gross proceeds of $3,023,250, with each unit consisting of one common share and one-half of one common share purchase warrant, each whole warrant exercisable at $2.25 per share for 24 months. The Company received a Compliant rating following a routine Health Canada inspection and initiated implementation of an ERP system. Cheelcare continued to advance Curio, its robotic complex-rehab power wheelchair, through product development, regulatory review, and initial commercialization, delivering its first Curio units to paying customers in March 2026.

Disagree with this article?